The bruton tyrosine kinase inhibitor ibrutinib (PCI‐32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach

No abstract is available for this paper.

• Publication year

  2014

• Venue

  British Journal of Haematology

• Publication date

  2014-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/bjh.12867PMID 24697238PMCID PMC4104473
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

  2013cited by this paper
• Hairy cell leukemia cell lines expressing annexin A1 and displaying B-cell receptor signals characteristic of primary tumor cells lack the signature BRAF mutation to reveal unrepresentative origins

  2013cited by this paper
• Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765)

  2013cited by this paper
• Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling.

  2013cited by this paper
• Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation.

  2012cited by this paper
• The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.

  2012cited by this paper
• The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.

  2012influential reference
• Cancer statistics, 2012

  2012cited by this paper
• Chronic lymphocytic leukemia: A tale of one or two signals?

  2012cited by this paper
• Hairy-cell leukemia variant: recent view on diagnosis, biology and treatment.

  2011cited by this paper
• Hairy cell leukaemia: biological and clinical overview from immunogenetic insights

  2011influential reference
• The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.

  2011cited by this paper
• Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

  2011cited by this paper
• Molecular insight into the biology and clinical course of hairy cell leukemia utilizing immunoglobulin gene analysis

  2011cited by this paper
• Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia.

  2011cited by this paper
• CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia.

  2011cited by this paper
• BRAF mutations in hairy-cell leukemia.

  2011cited by this paper
• The microenvironment in hairy cell leukemia: pathways and potential therapeutic targets

  2011cited by this paper
• Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

  2010cited by this paper
• CNS Disease In Younger Patients (

  2010cited by this paper
• Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

  2010cited by this paper
• The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

  2010cited by this paper
• B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.

  2009cited by this paper
• VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy.

  2009cited by this paper
• Long‐term follow‐up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis

  2009cited by this paper
• B lymphocytes: how they develop and function.

  2008cited by this paper
• Selective influences in the expressed immunoglobulin heavy and light chain gene repertoire in hairy cell leukemia

  2008cited by this paper
• High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation.

  2007cited by this paper
• WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues

  2007cited by this paper
• Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing.

  2007cited by this paper
• Immunophenotyping and differential diagnosis of hairy cell leukemia.

  2006cited by this paper
• CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment.

  2006cited by this paper
• Mechanisms of B-cell lymphoma pathogenesis

  2005cited by this paper
• Absence of surface CD27 distinguishes hairy cell leukemia from other leukemic B-cell malignancies.

  2005cited by this paper
• Chemokine Receptor Expression in B-cell Lymphoproliferative Disorders

  2004cited by this paper
• Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins.

  2004cited by this paper
• Multiple Distinct Sets of Stereotyped Antigen Receptors Indicate a Role for Antigen in Promoting Chronic Lymphocytic Leukemia

  2004cited by this paper
• Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia.

  2004cited by this paper
• The B Cell Antigen Receptor Controls Integrin Activity through Btk and PLCγ2

  2003cited by this paper
• Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope.

  2003cited by this paper
• The B cell antigen receptor controls integrin activity through Btk and PLC gamma 2

  2003cited by this paper
• Differential expression of chemokine receptors in B cell malignancies

  2001influential reference
• Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1.

  2000cited by this paper
• Cancer statistics

  1989cited by this paper

• Immune activation and microenvironmental crosstalk in hairy cell leukemia.

  2026cites this paper
• Long-term clinical outcome of a weekly 2-chlorodeoxyadenosine regimen in treatment-naïve patients with hairy cell leukemia

  2025cites this paper
• Microsecond simulations to investigate the structural mechanism of super-resistant double mutations in BTK to the covalent inhibitor ibrutinib in multiple leukemia

  2025cites this paper
• The tumor microenvironment in hairy cell leukemia (HCL) and splenic B cell lymphoma with prominent nucleoli (SBLPN)

  2025cites this paper
• Approach to hairy-cell leukemia in the new therapeutic era with special emphasis on age and comorbidities.

  2025cites this paper
• Ibrutinib Modulates Proliferation, Migration, Mitochondrial Homeostasis, and Apoptosis in Melanoma Cells

  2024cites this paper
• The role of the JunD-RhoH axis in the pathogenesis of hairy cell leukemia and its ability to identify existing therapeutics that could be repurposed to treat relapsed or refractory disease

  2024cites this paper
• Recommendations for the Management of Patients with Hairy-Cell Leukemia and Hairy-Cell Leukemia-like Disorders: A Work by French-Speaking Experts and French Innovative Leukemia Organization (FILO) Group

  2024cites this paper
• Hairy cell leukemia 2024: Update on diagnosis, risk‐stratification, and treatment—Annual updates in hematological malignancies

  2024cites this paper
• Hairy Cell Leukemia: Where Are We in 2023?

  2023cites this paper
• The protective role of the microenvironment in hairy cell leukemia treatment: Facts and perspectives

  2023cites this paper
• Treatment of Classic Hairy Cell Leukemia: Targeting Minimal Residual Disease beyond Cladribine

  2022cites this paper
• Novel targeted treatments in hairy cell leukemia and other hairy cell-like disorders

  2022cites this paper
• -----NRX-0492 Degrades Wildtype and C481 Mutant BTK and Demonstrates in vivo Activity in CLL Patient Derived Xenografts.

  2022cites this paper
• Measurable residual disease in hairy cell leukemia: Technical considerations and clinical significance

  2022cites this paper
• Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib

  2022cites this paper
• Hairy Cell Leukemia (HCL) and HCL Variant: Updates and Spotlights on Therapeutic Advances

  2022cites this paper
• B-cell receptor dependent phagocytosis and presentation of particulate antigen by chronic lymphocytic leukemia cells

  2022cites this paper
• Immunophenotypic Analysis of Hairy Cell Leukemia (HCL) and Hairy Cell Leukemia-like (HCL-like) Disorders

  2022cites this paper
• Advances in the Treatment of Hairy Cell Leukemia Variant

  2022cites this paper
• Targeting BTK Signaling in the Microenvironment of Solid Tumors as a Feasible Cancer Therapy Option

  2021cites this paper
• Current and Emerging Therapeutic Options for Hairy Cell Leukemia Variant

  2021cites this paper
• The resistance mechanisms and treatment strategies of BTK inhibitors in B‐cell lymphoma

  2021cites this paper
• Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continues

  2021cites this paper
• The Biology of Classic Hairy Cell Leukemia

  2021cites this paper
• In Vitro Sensitivity to Venetoclax and Microenvironment Protection in Hairy Cell Leukemia

  2021cites this paper
• Management of Relapsed Hairy Cell Leukemia: A Systematic Review of Novel Agents and Targeted Therapies.

  2021cites this paper
• OTT_A_242247 1797..1805

  2021cites this paper
• Phase 2 Study of Ibrutinib in Classic and Variant Hairy Cell Leukemia.

  2021cites this paper
• Hairy Cell Leukaemia

  2020cites this paper
• Analysis of four types of leukemia using Gene Ontology term and Kyoto Encyclopedia of Genes and Genomes pathway enrichment scores.

  2020cites this paper
• Biology and Treatment of Hairy Cell Leukemia

  2020cites this paper
• The pharmacological management of hairy cell leukemia.

  2020cites this paper
• Treatment of hairy cell leukemia

  2020cites this paper
• Guideline for diagnosis and management of hairy cell leukaemia (HCL) and hairy cell variant (HCL‐V)

  2020cites this paper
• Variant form of hairy cell leukemia

  2019cites this paper
• The CXCL12-CXCR4 signaling axis plays a key role in cancer metastasis and is a potential target for developing novel therapeutics against metastatic cancer.

  2019cites this paper
• Novel therapeutics in hairy cell leukemia

  2019cites this paper
• Hairy cell leukemia: present and future directions

  2019cites this paper
• No Loose Ends: A Review of the Pharmacotherapy of Hairy Cell and Hairy Cell Leukemia Variant

  2019cites this paper
• Update on hairy cell leukemia.

  2018cites this paper
• Water Solubility Enhancement of Pyrazolo[3,4-d]pyrimidine Derivatives via Miniaturized Polymer-Drug Microarrays.

  2018cites this paper
• Exploring the Pre-B receptor checkpoint as a therapeutic target in acute lymphoblasic leukaemia

  2018cites this paper
• Novel Therapies in Hairy Cell Leukemia

  2018cites this paper
• Molecular characterization and function analysis of grouper (Epinephelus coioides) Bruton's tyrosine kinase BTK

  2018cites this paper
• How I manage patients with hairy cell leukaemia

  2017influential citation
• Bruton's tyrosine kinase (BTK) as a promising target in solid tumors.

  2017cites this paper
• Chapter 27 – Ibrutinib

  2017cites this paper
• Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK.

  2017cites this paper
• Bone marrow mesenchymal stem cells regulate stemness of multiple myeloma cell lines via BTK signaling pathway.

  2017cites this paper
• Time to Cure Hairy Cell Leukemia

  2017cites this paper
• A Unique Hairy Cell Leukemia Variant

  2016cites this paper
• Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances

  2016cites this paper
• Radionuclide Therapy of Leukemias and Multiple Myeloma

  2016cites this paper
• Current Therapy and New Directions in the Treatment of Hairy Cell Leukemia: A Review.

  2016cites this paper
• Ibrutinib-A double-edge sword in cancer and autoimmune disorders

  2016cites this paper
• B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.

  2016cites this paper
• Hairy cell leukemia, an uncommon B-cell lymphoid neoplasia

  2016cites this paper
• Recent advances in diagnosis and treatment of hairy cell leukemia

  2015cites this paper
• Pharmacodynamic considerations of small molecule targeted therapy for treating B-cell malignancies in the elderly

  2015cites this paper
• Hairy cell leukemia: Past, present and future.

  2015cites this paper
• The importance of the tissue microenvironment in hairy cell leukemia.

  2015influential citation
• Potential breakthroughs with investigational drugs for hairy cell leukemia

  2015cites this paper
• Are Cladribine and Rituximab Enough for the Treatment of Relapsed Hairy Cell Leukemia

  2015cites this paper
• Novel therapeutic options for relapsed hairy cell leukemia

  2015cites this paper
• Current and emerging treatment options for hairy cell leukemia

  2015cites this paper
• Current Therapy and NewDirections in the Treatment of Hairy Cell Leukemia A Review

  2015cites this paper
• Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms

  2015cites this paper
• Targeting neoplastic B cells and harnessing microenvironment: the “double face” of ibrutinib and idelalisib

  2015cites this paper
• Targeting Bruton's tyrosine kinase with ibrutinib in B‐cell malignancies

  2015cites this paper
• Advances in the Treatment of Hairy Cell Leukemia

  2015cites this paper
• The Therapy of Hairy Cell Leukemia: The State of Art

  2015cites this paper
• [Chronic B-cell lymphoproliferative disorders with hairy cells].

  2015cites this paper
• Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2015cites this paper
• Ibrutinib: From Molecule to Medicine

  2014cites this paper
• Blood Research and Disorders Current Trends in Classic Hairy Cell Leukaemia: Aetiology, Diagnosis and Therapy

  year unknowncites this paper